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Asia-Pacific RegionHealth technology assessment (HTA) is rapidly evolving as new
frontiers are added to existing ones. Its pace of evolution is
remarkable even in the rapidly developing arena of the sciences.
Major developments have taken place with HTA, specifically in
methodology, as well as policymakers’ adoption of using HTA-
generated evidence in resource allocation decisions. Some recent
developments in methodology and policy are HTA usage for
personalized medicine, conjoint analysis, mixed treatment com-
parison, use of real-world data, coverage with evidence develop-
ment, risk-sharing scheme, and structured budget impact
analysis.
An increasing number of countries are adopting the use of
HTA to judiciously allocate scarce health resources. As more
countries use HTA as a policy decision-making tool, however,
every aspect of HTA, from methodology, modeling, analyses,
interpretation, to application of HTA evidence in policymaking,
has become the subject of intense debate among the various
health care sectors’ stakeholders, including technology develo-
pers, manufacturers, researchers, and policymakers. We reason
that the evolution in methodology and policy framework in HTA
has been accelerated in response to these debates, often being
initiated by technology developers and manufacturers as they try
to find ways to comply with the newer but tougher form of
regulation that is the HTA system.
Asia is no exception to the above transition in the HTA
environment. The region is also of strong interest in three
respects regarding HTA: 1) HTA has been gaining large momen-
tum in Asia; 2) Asia is a highly populated region offering a
significant customer pool for new health technology consump-
tion; and 3) the Asian economy on average is growing faster
than any other region in the globe, making the region an
attractive future market for the health technology industry.
For example, in addition to South Korea, Taiwan, and Thailand,
where HTA has been formally adopted for use in the health
care systems, Malaysia recently developed its pharmacoeco-
nomic guideline (PEG) and is now entering the stage of
implementation. Mainland China has also recently announced
its development of a PEG. In addition, the PEG of Indonesia
has now been signed by its Ministry of Health, and has
been implemented for internal use within the Office of the
Ministry of Health Indonesia [1]. In Japan, HTA and related
policy discussions are quickly developing at the government
Special Committee level, with the potential for implementation
in 2014 [1].
Because of these emerging trends in Asia, there has been
heightened interest in HTA among academic researchers, as wellial support: The authors have no other financial ras stakeholders such as policy makers, industry researchers, and
health practitioners. This Value in Health Regional Issues (ViHRI)
Asia issue, which is an extended arm of Value in Health (ViH) Asia
Special Issues of 2007, 2009, and 2011, witnessed this increase
first-hand through rising manuscript submissions on HTA
research. The increase in submissions reflects the trend of
pharmacoeconomics and outcomes research (PE-OR) develop-
ment in Asia.
Although the number of published articles in each issue
remained somewhat limited (22 articles for the first ViH Asia
Special Issue, 24 for the second, 20 for the third, and 20 for the
ViHRI Asia 2012), the number of submissions increased steadily,
reaching 67 submissions for the current issue of ViHRI Asia 2013.
After the editorial process, 23 manuscripts out of 67 were
accepted (34% acceptance rate), 39 manuscripts were rejected,
and 5 manuscripts were withdrawn during the process. The
submitted manuscripts were from 15 Asian regions, including
China, India, Indonesia, Vietnam, Pakistan, Japan, Taiwan, South
Korea, Malaysia, Hong Kong, Thailand, Iran, the Philippines, Sri
Lanka, and Nepal. Paper submissions coming from nearly all
Asian regions indicate that research interests on PE-OR are
existent and growing across all regions of Asia.
There is one thing to note regarding the manuscript submis-
sions. Of the 23 accepted manuscripts, the majority (13 manu-
scripts, 57%) are in the category of economic evaluation, followed
by 4 in quality of life, 2 in clinical outcomes, 2 in health policy,
and 2 in the conceptual analysis category. As is apparent, more
balance in research among the different categories of PE-OR
needs to be strived for. This lack of balance is likely due to the
short history of research in PE-OR in Asia as of yet. It is only very
recently that evidence-based health policy has been emphasized
and adopted in Asian health care systems. Over time, out of
diverse research needs and initiatives, balance in research in
various categories will likely be achieved.
An additional observation regarding the manuscripts is that
all the accepted manuscripts on economic analysis are country-
adaptation articles. As Professor Drummond pointed out in his
editorial in this issue [2], although there have been a few con-
ceptual papers discussing the impact of using particular meth-
ods, there were no articles thus far in ViH Asia Special Issues or
ViHRI discussing the use of new methodological approaches. This
is an area of research that needs to be explored in future ViHRI
issues.
PE-OR research in Asia faces challenges in many respects.
Drummond [2] summarizes the challenges, including research
manpower, data availability, and policy framework. Despite allelationships to disclose.
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advancing toward the adoption of HTA systems. All are working
toward efficient allocation of health resources through research-
based evidence whose costs will be outweighed by the benefits.
To realize such benefits, however, Asia needs to work on a
platform where the most recent research findings and valuable
information can efficiently be accessed by interested readers
and by policymakers to serve in resource allocation decisions.
The need for such a concrete platform rises with the increas-
ingly rapid development in HTA. This platform will function not
only as a connector of research and policy but also as an
accelerator of future avenues of research, and a facilitator of
policy framework development in a national setting. ViHRI is
willing to serve such a platform and play an indispensable role
in its development, with the entire editorial staff fully com-
mitted and ready to take on its share of responsibility to
achieve this.Bong-Min Yang, PhD
Seoul National University, Seoul, South Korea
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